Extended Data Fig. 1: Overview of biomarker analyses and associations between DFS and treatment arm by patient population. | Nature Medicine

Extended Data Fig. 1: Overview of biomarker analyses and associations between DFS and treatment arm by patient population.

From: Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial

Extended Data Fig. 1

a. Overview of biomarker analyses completed. b. Associations between DFS and treatment arm in all treated patients, the CD8 digital IHC-evaluable population and the CD8 digital IHC non-evaluable population. Shaded areas indicate 95% CI. c. Associations between DFS and treatment arm in all treated patients, the RNA-seq–evaluable population and the RNA-seq non-evaluable population. Shaded areas indicate 95% CI. d. Associations between DFS and treatment arm in all treated patients, the WES-evaluable population and the WES non-evaluable population. Shaded areas indicate 95% CI.

Back to article page